Biosimilar Newsletter Archive

  1. 11.15.18 -- Biosimilars Vs. AbbVie: "Humirapocalypse" Or Illusion?
    11/15/2018
    11/15/18 Biosimilar Development Newsletter
  2. 11.14.18 -- Business Strategies That Can Help Speed New Therapeutic Modalities To Market
    11/14/2018
    11/14/18 Biosimilar Development Newsletter
  3. 11.08.18 -- Biosimilars, Biobetters, Or Both?: Manufacturing Considerations
    11/8/2018
    11/08/18 Biosimilar Development Newsletter
  4. 11.05.18 -- Raw Material Management: Technology Advancements Improving Transparency And Collaboration
    11/5/2018
    11/05/18 Biosimilar Development Newsletter
  5. 11.01.18 -- What's Missing From Current Biosimilar Education?
    11/1/2018
    11/01/18 Biosimilar Development Newsletter
  6. 10.25.18 -- Humirageddon: Perspectives On The EU Biosimilar Launch
    10/25/2018
    10/25/18 Biosimilar Development Newsletter
  7. 10.24.18 -- Smash Bottlenecks In mAb Downstream Processing
    10/24/2018
    10/24/18 Biosimilar Development Newsletter
  8. 10.18.18 -- The Humira Biosimilar Tsunami: What To Expect
    10/18/2018
    10/18/18 Biosimilar Development Newsletter
  9. 10.16.18 -- Impurity Removal Using Various Chromatography Approaches
    10/16/2018
    10/16/18 Biosimilar Development Newsletter
  10. 10.15.18 -- Scale-Up And Scale-Out With Single-Use Fermentors
    10/15/2018
    10/15/18 Biosimilar Development Newsletter